The results of a large pan-European study by the European Study Group for Pancreatic Cancer (ESPAC) involving 732 patients has shown that the combination of gemcitabine plus capecitabine adjuvant therapy (following successful resection of the tumour) significantly improved survival. Presented at the American Society for Clinical Oncology1 in Chicago this week, the lead researchers fromRead More »Two-drug combination improves survival for operable pancreatic cancer
We have seen a lot in the press recently about the advances in immunotherapy for many cancers and, in the case of melanoma, with extraordinary results. We’ve not as yet seen this happen for pancreatic cancer which, so far, has proven difficult to treat with either conventional chemotherapy and/or novel immunotherapy. Some trials of immunotherapyRead More »Have we now found a way for immunotherapy to work in pancreatic cancer too?